Alimera Sciences, Inc.
ALIM
ALIM: Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
moreShow ALIM Financials
Recent trades by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ALIM's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods of treating retinal diseases Aug. 02, 2022
-
Patent Title: Ocular implantation device Dec. 26, 2017
-
Patent Title: Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids Mar. 26, 2013
Federal grants, loans, and purchases
Followers on company's Twitter account
Number of mentions of ALIM in WallStreetBets Daily Discussion
Recent insights relating to ALIM
Recent picks made for ALIM on CNBC
ETFs with the largest estimated holdings in ALIM
Flights by private jets registered to ALIM